Abbott Laboratories
HealthcareNYSE:ABT · New York Stock Exchange
-$1.89 today
Vol 6.22M · Avg 12.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.5%
avg 14.2%
ROIC
8.4%
avg 7.6%
ROA
7.5%
avg 7.2%
Analysis
ROE is currently the strongest return metric at 12.5% versus its period average of 14.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Ford | Chairman, Pres & Chief Executive Officer | $4.43M | — | 52 | $10,544.00 | <0.01% |
Elizabeth Cushman | Executive Vice President, General Counsel & Secretary | $2.55M | — | 56 | $38,573.00 | <0.01% |
Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices | $2.39M | — | 56 | $90,407.00 | <0.01% |
Philip Boudreau | Chief Financial Officer & Executive Vice President of Finance | $2.10M | — | 53 | $9,276.00 | <0.01% |
Christopher J. Scoggins | Executive Vice President of Diabetes Care | $2.06M | — | 56 | $77,126.00 | <0.01% |
Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products | $1.52M | — | 47 | $6.75M | 0.39% |
Michael Comilla | Vice President of Investor Relations. | — | — | — | $10,764.00 | <0.01% |
Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer | — | — | 52 | — | — |
Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer | — | — | — | $39,162.00 | <0.01% |
Melissa Brotz | Senior Vice President of Global Marketing & External Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$4.23M
Sells
8
$1.44M
Net Sentiment
+$2.79M
Net buying
Most Active
STARKS DANIEL J
3 transactions
1–10 of 13
Analysis
Insiders reported 5 buys worth $4.23M and 8 sells worth $1.44M over the last 12 months. That adds up to net buying of $2.79M. STARKS DANIEL J was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -7.8% | +7.2% (15yr)3 analysts |
| Revenue | N/A | N/A | -20.0% | +8.4% (15yr)9 analysts |
| Net Income | N/A | N/A | -9.5% | +8.3% (15yr)9 analysts |
| EBIT | N/A | N/A | +13.7% | +10.5% (15yr)9 analysts |
Analysis
Recent growth has been strongest in EBIT at +13.7% over three years. Forward estimates point to EBIT at +10.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
UnitedHealth Group Incorporated
NYSE:UNH
$370.42B
Merck & Co., Inc.
NYSE:MRK
$296.05B
Novartis AG
NYSE:NVS
$292.70B
Novo Nordisk A/S
NYSE:NVO
$196.75B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.38B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.38B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$144.53B
Stryker Corporation
NYSE:SYK
$120.34B
Medtronic plc
NYSE:MDT
$103.17B
Boston Scientific Corporation
NYSE:BSX
$69.91B
Who manages ABT?
Abbott Laboratories (ABT) lists 10 active executives. The top listed executive is Michael Comilla, Vice President of Investor Relations..
Are ABT insiders buying or selling?
Recent insider activity shows net buying of $77.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.